Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1228-1232

  Masci, G ^a   di Tommaso, L ^a   del Prato, I ^b   Orefice, S ^c   Rubino, A ^c   Gullo, G ^a   Zuradelli, M ^a   Sacco, R ^b   Alloisio, M ^d   Eboli, M ^c   Incarbone, M ^d   Giordano, L ^d   Roncalli, M ^a   Santoro, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

^c Unit of Senology   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Breast; Cancer; Lymph node; Micrometastasis; Prognosis

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MICROMETASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; TUMOR VOLUME; AGED; BREAST NEOPLASMS; CARCINOMA; EVALUATION STUDY; FEMALE; LYMPH NODE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TISSUE DISTRIBUTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 77953127181     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp453     Document Type: Article

References (30)

1. Greene FL, Page DL, Fleming ID et al. American Joint Committee on Cancer Staging Manual, 6th edition. New York, NY: Springer 2002.
2. Chagpar A, Middleton LP, Sahin AA et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 2005; 103: 1581-1586.
3. Kahn HJ, Hanna WM, Chapman JA et al. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 2006; 12: 294-301.
4. Millis RR, Springall R, Lee AH et al. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002; 86: 396-401.
5. Braun S, Cevatli BS, Assemi C et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001; 19: 1468-1475.
6. Cox CE, Kiluk JV, Riker AL et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 2008; 206: 261-268.
7. Tan LK, Giri D, Hummer AJ et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008; 26: 1803-1809.
8. Susnik B, Frkovic-Grazio S, Brako M. Occult micrometastases in axillary lymph node predict subsequent distant metastases in stage I breast cancer: a casecontrol study with 15-year follow-up. Ann Surg Oncol 2004; 11: 568-572.
9. Grabau D. Breast cancer patients with micrometastases only: is a basis provided for tailored treatment? Surg Oncol 2008; 17: 211-217.
10. Viale G, Maiorano E, Pruneri G et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005; 241: 319-325.
11. Di Tommaso L, Arizzi C, Rahal D et al. Anatomic location of breast cancer micrometastasis in sentinel lymph node predicts axillary status. Ann Surg 2006; 243: 706-707.
12. Li J, Rudas M, Kemmner W et al. The location of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast cancer patients. Eur J Surg Oncol 2008; 34: 857-862.
13. Colleoni M, Rotmensz N, Peruzzotti G et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005; 23: 1379-1389.
14. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours, 6th edition. New York, NY: Wiley-Liss 2002.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002; 41: 151-152.
16. Rosen PP, Oberman H. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology 1993.
17. Viale G, Bosari S, Mazzarol G et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999; 85: 2433-2438.
18. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
19. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
20. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
21. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496.
22. Moliterni A, Bonadonna G, Valagussa P et al. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991; 9: 1124-1130.
23. Chlebowski RT, Col N, Winer EP et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20: 3328-3343.
24. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years of adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
26. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Cox D. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
28. Garassino I, Gullo G, Orefice S et al. Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy. The Breast 2009; 18: 263-266.
29. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast metastasis. Nature 2001; 410: 50-56.
30. Takeuchi H, Fujimoto A, Tanaka M et al. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004; 10: 2351-2380.